Global Narcolepsy Drugs Market Report (2022 to 2027) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – Yahoo Finance

DUBLIN, Oct. 24, 2022 /PRNewswire/ — The “Narcolepsy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to’s offering.

The global narcolepsy drugs market reached a value of US$ 2.84 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 4.5 Billion by 2027, exhibiting a CAGR of 7.97% during 2021-2027.
Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Narcolepsy drugs refer to pharmaceutical medicines used for the treatment of chronic sleep disorders. The disorder is characterized by excessive daytime sleepiness (EDS), cataplexy or sudden loss of muscle strength, sleep paralysis, hallucinations, fragmented sleep and insomnia.
Additional symptoms may include automatic behaviors without conscious awareness, blurred vision, double vision or droopy eyelids and disturbed mental functioning. Patients suffering from narcolepsy tend to sleep the same number of hours per day as normal individuals; however, sleep quality tends to be poorer.
Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants. These drugs aid in improving wakefulness in adult patients and minimizing hallucinations, sleepiness and cataplexy.

The increasing prevalence of narcolepsy across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the working population, which, in turn, is significantly increasing the incidences of sleep-related disorders.
Moreover, rising health consciousness among the masses and the increasing awareness regarding the available treatment alternatives are providing a thrust to the market growth. In line with this, the widespread adoption of sodium oxybate for the treatment of narcolepsy in children is also contributing to the growth of the market.
Additionally, significant improvements in the diagnostic technologies for narcolepsy are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing variants with long-term benefits and reduced side effects. Other factors, including the rising geriatric population, which is more susceptible to such ailments, along with extensive research and development (R&D) activities in the field of neurology, are anticipated to drive the market toward growth.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Bioprojet Pharma, Graymark Healthcare Inc., Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis AG, SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:
How has the global narcolepsy drugs market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global narcolepsy drugs market?
What are the key regional markets?
What is the breakup of the market based on the type?
What is the breakup of the market based on the disease type?
What is the breakup of the market based on the therapeutic type?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global narcolepsy drugs market and who are the key players?
What is the degree of competition in the industry?
Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Narcolepsy Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type
6.1 Narcolepsy with Cataplexy
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Narcolepsy without Cataplexy
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Secondary Narcolepsy
6.3.1 Market Trends
6.3.2 Market Forecast

7 Market Breakup by Disease Type
7.1 Daytime Extreme Sleepiness
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Cataplexia
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast

8 Market Breakup by Therapeutic Type
8.1 Sodium Oxybate
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Central Nervous System Stimulants
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Tricyclic Antidepressants
8.3.1 Market Trends
8.3.2 Market Forecast
8.4 Selective Serotonin Reuptake Inhibitor
8.4.1 Market Trends
8.4.2 Market Forecast
8.5 Others
8.5.1 Market Trends
8.5.2 Market Forecast

9 Market Breakup by Region

10 SWOT Analysis

11 Value Chain Analysis

12 Porters Five Forces Analysis

13 Price Analysis

14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Avadel Pharmaceuticals plc Company Overview Product Portfolio Financials SWOT Analysis
14.3.2 Axsome Therapeutics Inc. Company Overview Product Portfolio Financials
14.3.3 Bioprojet Pharma Company Overview Product Portfolio
14.3.4 Graymark Healthcare Inc. Company Overview Product Portfolio
14.3.5 Jazz Pharmaceuticals plc Company Overview Product Portfolio Financials SWOT Analysis
14.3.6 Ligand Pharmaceuticals Incorporated Company Overview Product Portfolio Financials SWOT Analysis
14.3.7 Novartis AG Company Overview Product Portfolio Financials SWOT Analysis
14.3.8 SHIONOGI & Co. Ltd. Company Overview Product Portfolio Financials SWOT Analysis
14.3.9 Takeda Pharmaceutical Company Limited Company Overview Product Portfolio Financials SWOT Analysis
14.3.10 Teva Pharmaceutical Industries Ltd. Company Overview Product Portfolio Financials SWOT Analysis
For more information about this report visit
Logo –
Media Contact:
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:—industry-trends-share-size-growth-opportunity-and-forecasts-301657160.html
SOURCE Research and Markets
Shares of many Chinese companies are getting hit hard today, including several of China's electric vehicle (EV) makers. Shares of Nio (NYSE: NIO), XPeng (NYSE: XPEV), and Li Auto (NASDAQ: LI) all plunged by double digits Monday morning. As of 10:53 a.m. ET, Nio shares were down 20.6%, XPeng was lower by 18.8%, and Li Auto had plunged 24.1%.
Amazon's (AMZN) third-quarter results are expected to reflect strength across its Prime and cloud businesses despite headwinds.
THE MONEYIST Dear Quentin,  I am a senior citizen and have suffered major losses to the tune of $100,000 in the recent stock market turmoil. Can I sue my financial adviser? I understand the dynamics of the market as far as its ups and downs, and have ridden them out before.
Wall Street's skepticism continues to feed Main Street's fears about this growth stock's prospects.
In this article, we will look at the 10 most undervalued value stocks to buy now. If you want to explore similar stocks, you can also take a look at 5 Most Undervalued Value Stocks To Buy Now. 2022 has been an unfavorable year for stocks so far due to rampant inflation and high interest […]
Considering the tough macro environment and its impact on the markets, investors can be forgiven for some indecision when it comes to choosing stocks right now. But there are clues, hints that will point out the right stocks, even in an unsettled market. The simplest move, of course, is to look for quality stocks that have fallen sharply in recent months, down to bargain-level prices. The adage is 'buy low and sell high,' and fundamentally sound stocks that have fallen 50% or more in less than a
But Wood's flagship Ark Innovation ETF has tumbled 63% so far this year, dropping 78% from its February 2021 peak.
Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), United Parcel Service, Inc. (UPS) and Devon Energy Corporation (DVN).
Southern Copper Corporation ( NYSE:SCCO ) has announced that on 23rd of November, it will be paying a dividend of$0.50…
Yahoo Finance Live anchors discuss the earnings expectations for Tech giants like Google, Microsoft, and Meta.
KeyBanc analyst Josh Beck lowered his price target on Shopify from $50 to $45 while simultaneously maintaining his overweight (buy) rating on the stock, according to The Fly. The analyst has been reading the digital tea leaves and studying various proxies for Shopify's gross merchandise volume (GMV) and gross payment volume (GPV) — the most widely followed measures of the company's success. While Shopify's growth is certainly worth watching, it's best if we wait to hear the actual number from the company rather than relying on estimates.
The U.S.-listed shares of China-based companies took broad beating Monday, as China President Xi Jinping's moves to consolidate power fueled fears that current policies that have led to a slowing economy will continue.
Shares of the online car marketplace Carvana (NYSE: CVNA) were tumbling today, despite market indexes making gains. Carvana's stock may have been falling as investors continue to process a price target cut from an analyst on Friday. Additionally, investors are likely concerned that high inflation and a potentially slowing economy could negatively impact the company's quarterly results, which will be reported next week.
Kinder Morgan (NYSE: KMI) is the undisputed leader in natural gas infrastructure. The company owns and operates 70,000 miles of pipelines, giving it the largest natural gas network in North America. It transports 40% of the natural gas consumed in the U.S. each day.
The reaction to President Xi's new power has been swift but I don't think it'll be discounted in one trading session.
This year we saw declines pretty much across the board, with the S&P 500 tumbling ~20%. But last week was the index’s best week since June – the S&P had a weekly gain of about 4.7%. We’ve seen several of these bounces this year, and the question is, are they bullish indicators or merely 'dead cats'? According to Oppenheimer’s chief investment strategist John Stoltzfus, it shouldn't really make a difference whether we’re looking at bullish indicators or bear market rallies. The key here is simply
DEEP DIVE Investors have made one thing clear: They don’t like Xi Jinping’s moves to consolidate power. Over the weekend, Xi took his third term as China’s communist party leader while sidelining rivals, extending his rule without an heir apparent.
The average of price targets set by Wall Street analysts indicates a potential upside of 27.4% in Energy Transfer LP (ET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
In this article, we discuss 11 best low risk stocks to buy in 2022. If you want to see more stocks in this selection, check out 5 Best Low Risk Stocks To Buy In 2022. Amid the volatile market environment, investors are scurrying to pull out their investments and sit on cash stockpiles, or at […]
Occidental Petroleum, a Warren Buffett favorite, is approaching a buy point as profitability rises ahead of Q3 earnings.


Add a Comment

Your email address will not be published. Required fields are marked *